ReviewJournal of molecular cell biology2012
CD4(+)Foxp3(+) regulatory T cell therapy in transplantation.
Review in Journal of molecular cell biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02088931 (A Pilot Trial of CD4+CD127lo/-CD25+ Polyclonal Treg Adoptive Immunotherapy in Renal Transplant Recipients), which is not on this map. Cited by 84 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Trial of CD4+CD127lo/-CD25+ Polyclonal Treg Adoptive Immunotherapy in Renal Transplant Recipients
Who cites it
84 citing papers in PubMed, 159 citations in OpenAlex.
- Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.Journal of autoimmunity · 2015Trial
- Human cytomegalovirus latency-associated proteins elicit immune-suppressive IL-10 producing CD4⁺ T cells.PLoS pathogens · 2013Trial
- HLA-A2 CAR/IL-2-CISC engineered Treg display robustMolecular therapy. Methods & clinical development · 2025Article
- Monitoring regulatory T cells as a prognostic marker in lung transplantation.Frontiers in immunology · 2023Review
- High-performance multiplex drug-gated CAR circuits.Cancer cell · 2022Article
- Localization and movement of Tregs in gastrointestinal tract: a systematic review.Inflammation and regeneration · 2022Review
- Review
- Cell therapy in vascularized composite allotransplantation.Biomedical journal · 2022Review
- Biomarkers of immune tolerance in kidney transplantation: an overview.Pediatric nephrology (Berlin, Germany) · 2022Review
- Intestinal Regulatory T Cells as Specialized Tissue-Restricted Immune Cells in Intestinal Immune Homeostasis and Disease.Frontiers in immunology · 2021Review
- Targeting Enclysis in Liver Autoimmunity, Transplantation, Viral Infection and Cancer.Frontiers in immunology · 2021Review
- Interleukin-5 (IL-5) Therapy Prevents Allograft Rejection by Promoting CD4Frontiers in immunology · 2021Article
- Low-Dose IL-2 Therapy in Transplantation, Autoimmunity, and Inflammatory Diseases.Journal of immunology (Baltimore, Md. : 1950) · 2019Review
- Local Delivery of Regulatory T Cells Promotes Corneal Allograft Survival.Transplantation · 2019Article
- Alloactivation of Naïve CD4Frontiers in immunology · 2019Article
- Superior immune reconstitution using Treg-expanded donor cells versus PTCy treatment in preclinical HSCT models.JCI insight · 2018Article
- Very Low Numbers of CD4Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018Article
- Targeting Antigen-Specific B Cells Using Antigen-Expressing Transduced Regulatory T Cells.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- Immune Mechanisms and Pathways Targeted in Type 1 Diabetes.Current diabetes reports · 2018Review
- Functional Defects of Treg Cells: New Targets in Rheumatic Diseases, Including Ankylosing Spondylitis.Current rheumatology reports · 2018Review
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Regulatory T cells (Tregs) are long-lived cells that suppress immune responses in vivo in a dominant and antigen-specific manner. Therefore, therapeutic application of Tregs to control unwanted immune responses is an active area of investigation. Tregs can confer long-term protection against auto-inflammatory diseases in mouse models. They have also been shown to be effective in suppressing alloimmunity in models of graft-versus-host disease and organ transplantation. Building on extensive research in Treg biology and preclinical testing of therapeutic efficacy over the past decade, we are now at the point of evaluating the safety and efficacy of Treg therapy in humans. This review focuses on developing therapy for transplantation using CD4(+)Foxp3(+) Tregs, with an emphasis on the studies that have informed clinical approaches that aim to maximize the benefits while overcoming the challenges and risks of Treg cell therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.